🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› France
Clinical trial register · European Union · CTIS

Clinical Trials in France

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
89 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer
2025-524690-16-00Solid Tumors
Theras Inc.
Neoplasms
Spain, Italy, France
16/06/2026
Phase I
A Safety Study to Test a New Medicine (ANT3310) Alone and When Taken with an Antibiotic (Meropenem) in Healthy Adult Participants.
2026-526411-11-00Not applicable for phase I study
Antabio
Not possible to specify
France
12/06/2026
Phase I
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers
2026-525700-10-00Schizophrenia
Syremis Therapeutics Ltd.
Mental Disorders
France
08/06/2026
Phase I
First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors
2025-524165-25-00Neoplasms
Glaxosmithkline Research & Development Limited
Neoplasms
Spain, Denmark, Finland, France
21/05/2026
Phase I
A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease
2024-517310-15-00Parkinson's Disease
Mission Therapeutics Limited
Nervous System Diseases
Germany, Netherlands, France
18/05/2026
Phase I
First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors
2025-521173-13-00Advanced Solid Tumors
Daiichi Sankyo Inc.
Neoplasms
France, Spain
08/05/2026
Phase I
Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer
2025-522888-15-00Small Cell Lung Cancer
Amgen Inc.
Neoplasms
Spain, Germany, Poland, Belgium, France
05/05/2026
Phase I
​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors ​
2025-524056-63-00microsatellite instability high/mismatch repair deficient (…
Amgen Inc.
Neoplasms
Spain, France, Belgium
28/04/2026
Phase I
Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis
2025-522904-26-00Systemic Lupus Erythematosus (SLE) With or Without Active L…
Genentech Inc.
Immune System Diseases
Italy, Spain, France, Germany
22/04/2026
Phase I
A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)
2025-522913-45-00Advanced relapsed or refractory ovarian cancer, Advanced re…
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Spain, France, Belgium, Germany
20/04/2026
Phase I
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).
2024-520125-36-00Relapsed or Refractory Acute Myeloid Leukemia; Acute Myelo…
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Hungary, Czechia, France, Italy, Belgium
20/04/2026
Phase I
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
2025-524136-19-00Selected Advanced or Metastatic Solid Tumors
BeOne Medicines AG
Neoplasms
Italy, France
15/04/2026
Phase I
A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer
2025-521000-22-00Patients with advanced malignancies
Novartis Pharma AG
Neoplasms
Spain, Italy, France
14/04/2026
Phase I
Single-centre Phase I/II study with dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy in patients with Acute Myeloid Leukaemia (AML): TOCIVENA
2025-524725-41-00Acute Myeloblastic Leukemia
Centre Hospitalier Universitaire De Nantes
Not possible to specify
France
10/04/2026
Phase I
A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer
2025-521001-40-00Advanced Malignancies and Hepatic Impairment
Novartis Pharma AG
Neoplasms
Spain, France, Italy
09/04/2026
Phase I
A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.
2025-524157-13-00Chronic Hepatitis B
Precision Biosciences Inc.
Virus Diseases
Romania, France
08/04/2026
Phase I
A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.
2025-522932-15-00Systemic Lupus Erythematosus
Glaxosmithkline Research & Development Limited
Immune System Diseases
Germany, France, Italy, Spain, Poland
23/03/2026
Phase I
Phase 1 trial of valemetostat and darolutamide in mCRPC
2025-522512-16-00Metastatic Castration Resistant Prostate Cancer (mCRPC)
Daiichi Sankyo Inc.
Neoplasms
Ireland, Spain, France
18/03/2026
Phase I
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
2025-523686-15-00Advanced or Metastatic Solid Tumors
Olema Pharmaceuticals Inc.
Neoplasms
Ireland, Spain, France
17/03/2026
Phase I
Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease
2025-523845-90-00Relapsed/Refractory Hematologic Autoimmune Disease
CRISPR Therapeutics AG
Hemic and Lymphatic Diseases
Spain, Germany, France, Denmark, Italy, Netherlands
12/03/2026
Phase I
C6001001 - A Study to Learn about the Study Medicine PF-08052667 in People with Bladder Cancer.
2025-521756-39-00Non-muscle invasive bladder cancer (NMIBC)
Pfizer Inc.
Neoplasms
France, Spain
02/03/2026
Phase I
Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs
2025-523297-16-00Non-Hodgkin Lymphoid Malignancies (NHLs)
Janssen Cilag International
Neoplasms
Belgium, France, Spain
26/02/2026
Phase I
A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)
2025-521438-27-00advanced, unresectable and/or metastatic solid tumors
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Sweden, France, Spain, Germany
19/02/2026
Phase I
A Phase 1 Study of IM-1021 in Participants with Advanced Cancer
2025-523160-20-00Advanced B-cell lymphomas, Advanced solid tumors
Immunome Inc.
Neoplasms
France, Spain, Denmark, Italy
16/02/2026
Phase I
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
2025-521702-18-00Locally advanced unresectable or metastatic soft tissue sar…
Novartis Pharma AG
Neoplasms
Germany, Portugal, France, Spain, Denmark
16/02/2026
Rows per page Showing 26–50 of 89
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe/country/france

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.